Loading...
•
Dec 31, 2023
Iovance Q4 2023 Earnings Report
Iovance reported fourth quarter and full year 2023 financial results and corporate updates, highlighted by the ongoing U.S. launch of Amtagvi™ and progress in regulatory submissions in Europe, the United Kingdom, and Canada.
Key Takeaways
Iovance Biotherapeutics reported fourth quarter 2023 financial results, featuring a net loss of $116.4 million, or $0.45 per share, and revenue of $0.5 million from Proleukin® sales following its acquisition in May 2023. The company's cash position is expected to fund operations well into the second half of 2025, with the U.S. launch of Amtagvi™ underway and regulatory submissions planned in Europe, the UK, and Canada.
Amtagvi™ U.S. launch is fully underway following FDA approval as the first and only one-time, individualized T cell therapy for a solid tumor cancer.
Regulatory submissions for Amtagvi are on track in the European Union, United Kingdom, and Canada.
Amtagvi patients have been identified at nearly all of the 30 authorized treatment centers (ATCs), with approximately 50 ATCs anticipated to be ready by the end of May 2024.
Iovance had $346.3 million in cash, cash equivalents, investments and restricted cash at December 31, 2023.
Revenue by Segment
Forward Guidance
Iovance expects its cash position, including net proceeds from a February 2024 stock offering and anticipated revenue from Amtagvi and Proleukin, to be sufficient to fund current and planned operations well into the second half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...